Trial Profile
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2021
Price :
$35
*
At a glance
- Drugs Blarcamesine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Expanded access
- Acronyms EXCELLENCE
- Sponsors Anavex Life Sciences
- 16 Mar 2021 Results presented in an Anavex Life Sciences media release.
- 11 Jan 2021 Status changed from active, no longer recruiting to completed.
- 05 Aug 2020 According to an Anavex Life Sciences media release, the TGA approved the Special Access Scheme Category B applications based on the safety profile of ANAVEX2-73 (blarcamesine), as well as clinical evidence that ANAVEX2-73 (blarcamesine) may benefit patients. Anavex will facilitate continued access to ANAVEX2-73 (blarcamesine) through the Special Access Scheme at the physicians request.